Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 165, Issue 1-2, Pages 41-52Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2005.04.009
Keywords
autoimmunity; experimental allergic encephalomyelitis; multiple sclerosis; T cells; tolerance
Categories
Funding
- Multiple Sclerosis Society [541] Funding Source: Medline
Ask authors/readers for more resources
To date there has been poor translation of immunotherapies from rodent models to treatment of progressive multiple sclerosis (MS). In the robust, relapsing Biozzi ABH mouse model of MS, using a combination of a transient deletion of T cells followed by intravenous (i.v.) myelin antigen administration, established relapsing disease in EAE can be effectively silenced. However, when treatment was initiated in late stage chronic-relapsing disease, despite inhibition of further relapses, mice demonstrated evidence of disease progression shown by a deterioration in mobility and development of spasticity and indicates that targeting relapsing, immunological components of MS alone is unlikely to be sufficient to control progression in the late stages of MS. (C) 2005 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available